Compare Summit Therapeutics Inc (SMMT) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Snowflake Inc — how do they compare? Summit Therapeutics Inc trades at $17.45 (market cap $13.71B), while Snowflake Inc trades at $366.83 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 8.8× Summit Therapeutics Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Snowflake Inc for 54 Days on average.
| SMMT | SNOW | |
|---|---|---|
Market Cap | $13.71B | $121.15B |
Volume | 6,173,057 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $26.38 | $356.47 |
52-Week Low | $12.43 | $121.11 |
Typical Hold Time | 16 Days | 54 Days |
Enterprise Value | $13.04B | $121.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Snowflake (SNOW) trades at $360.12, up 8.19% in the past 24 hours, with strong technical momentum and bullish moving average signals. The company continues to show impressive revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a net loss of $1.29 billion. Recent developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath, while analysts maintain strong buy sentiment with an $418.03 consensus price target.
Snowflake presents a growth investment opportunity with accelerating revenue expansion and positive earnings beats, but faces significant execution risk due to persistent losses and high valuation multiples. The stock's 81% analyst buy rating reflects confidence in the company's AI data cloud positioning, though investors must weigh the premium valuation against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
